Cellectis S.A. (NASDAQ:CLLS) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. reduced its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 58.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 290,429 shares of the biotechnology company’s stock after selling 403,510 shares during the period. Baillie Gifford & Co.’s holdings in Cellectis were worth $523,000 at the end of the most recent quarter.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Barclays reduced their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. StockNews.com initiated coverage on Cellectis in a research note on Wednesday. They issued a “buy” rating on the stock.

Cellectis Stock Performance

Shares of NASDAQ CLLS opened at $1.58 on Wednesday. The stock has a 50 day moving average of $1.65 and a 200-day moving average of $1.92. The company has a market capitalization of $87.54 million, a P/E ratio of -1.21 and a beta of 3.06. Cellectis S.A. has a 12 month low of $1.41 and a 12 month high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.